ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2282

Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2110

Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases

(2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2373

Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2016

Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 74 patients

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2205

Effectiveness of Reproductive Health Counseling for Rheumatology Patients

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

10:30AM-12:30PM: Abstract Number: 2281

Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2552

Effects of 360° Virtual Reality Embodiment Videos on Pain in Hand Osteoarthritis: A Within-Subject Pre-Post Study

(2547–2566) ARP Posters I

10:30AM-12:30PM: Abstract Number: 2289

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2050

Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2348

Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2014

Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2013

Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: LB08

Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study

(LB01–LB18) Late-Breaking Posters

10:30AM-12:30PM: Abstract Number: 2488

Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: LB11

Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study

(LB01–LB18) Late-Breaking Posters

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].